COMMUNIQUÉS West-GlobeNewswire

Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations
01/08/2018
REDUCE-IT™ Study On-Track for Reporting Top-Line Results by the End of September 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 01, 2018 (GLOBE NEWSWIRE) -- [...]
Shire plc : Half-year Report
01/08/2018
Half-yearly Report August 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), ("Shire" / the "Company"/ the "Group") in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, is [...]
Shire plc : Rule 2.9 Announcement
01/08/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 1 August 2018 [...]
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
01/08/2018
This three-way crossover study will inform design of pivotal Phase 3 trials Top line data expected first quarter 2019 LONDON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma [...]
Kiadis Pharma secures €20 million debt financing facility from Kreos Capital
01/08/2018
Kiadis Pharma secures €20 million debt financing facility from Kreos Capital Amsterdam, The Netherlands, August 1, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a [...]
REVA to Hold Second Quarter 2018 Financial Results Call
01/08/2018
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) has scheduled a conference call to review its second quarter 2018 financial results and provide a business update. The [...]
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
01/08/2018
LA JOLLA, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke
01/08/2018
GERMANTOWN, Md., July 31, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/2018
CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat [...]
Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan
31/07/2018
LAVAL, QUÉBEC, July 31, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced the mailing of its management information circular for the upcoming annual [...]
Global Kinetics Corporation’s Personal KinetiGraph™ Welcomes New Category III CPT® Codes for Use in Parkinson’s Care
31/07/2018
Leading Parkinson’s measurement company Global Kinetics reaches major milestone with issue of US CPT III codes PORTSMOUTH, N.H. and LONDON and MELBOURNE, Australia, July 31, 2018 (GLOBE NEWSWIRE) -- Global Kinetics Pty [...]
James E. Wagner Cultivation Corporation Signs Cannabis Concentrate Program Agreement With MediPharm Labs Inc.
31/07/2018
TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- James E. Wagner Cultivation Corporation (TSX VENTURE:JWCA) (" JWC " or the " Company ") is pleased to announce that it has entered into a Cannabis Concentrate Program Agreement [...]
Resverlogix Intends to Pursue U.S. Listing
31/07/2018
CALGARY, Alberta, July 31, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it intends to pursue a listing of its common shares in the United States. Accordingly [...]
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Conference Call
31/07/2018
CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its [...]
Northwell, North American Partners in Anesthesia renew anesthesiology services agreement
31/07/2018
NEW HYDE PARK, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- Northwell Health and North American Partners in Anesthesia (NAPA) announced today they have signed a new five-year agreement to provide anesthesiology services at [...]
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
31/07/2018
SOUTH SAN FRANCISCO, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
31/07/2018
- Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18 - - Cash Position of $253.8 Million at Quarter-End - [...]
Profound Medical to Present at the Canaccord Genuity 38th Annual Growth Conference
31/07/2018
TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time [...]
Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
31/07/2018
ZIKV-IG granted Fast Track designation by the U.S. Food and Drug Administration GAITHERSBURG, Md., July 31, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1 [...]

Pages